On January 30, CMS announced that Dermavon, a subsidiary of the company, had received NMPA approval for the new drug application for ruxolitinib phosphate cream for the treatment of nonsegmental vitiligo with facial involvement in children aged 12 years and older and adults. It is the first and only targeted drug approved in China for vitiligo treatment, addressing a major unmet clinical need.
Ruxolitinib phosphate cream (Opzelura) is an innovative cream formulation of ruxolitinib, a selective JAK1/JAK2 inhibitor developed by Incyte.
In the United States, the drug is approved for the topical treatment of nonsegmental vitiligo in adults and patients aged 12 years and older, and for short-term and non-continuous chronic topical treatment of mild to moderate atopic dermatitis in non-immunocompromised patients aged 2 years and older.
In Europe, ruxolitinib phosphate cream is approved for adults and adolescents aged 12 years and older with nonsegmental vitiligo involving the face.
According to Incyte’s financial disclosures, global sales of ruxolitinib phosphate cream exceeded USD 500 million in 2024, up more than 50% year over year.
In December 2022, through a Dermavon subsidiary, CMS entered into a collaboration and license agreement with Incyte for ruxolitinib phosphate cream, obtaining exclusive rights to develop, register, and commercialize the product in mainland China, Hong Kong SAR, Macao SAR, Taiwan region, and 11 Southeast Asian countries, as well as non-exclusive manufacturing rights within the territory. The relevant rights outside mainland China were sublicensed to CMS by the Dermavon subsidiary, excluding Dermavon and its affiliates.
In overseas clinical studies, ruxolitinib phosphate cream delivered positive results. In two identically designed Phase III double-blind, randomized, placebo-controlled studies, TRuE-V1 and TRuE-V2, the proportion of patients achieving the primary endpoint of at least 75% improvement in the Facial Vitiligo Area Scoring Index (F-VASI 75) after 24 weeks was 29.9% in both studies, significantly higher than the placebo groups at 7.5% and 12.9%. Repigmentation benefits were sustained through 52 weeks of continued treatment.
In China, CMS previously launched a real-world study of ruxolitinib phosphate cream. Results showed positive efficacy consistent with the key overseas clinical studies.
In addition, all secondary efficacy endpoints in domestic and international clinical studies showed benefit trends consistent with the primary endpoint, and vitiligo treatment effects continued to improve with longer treatment duration.
Beyond the newly approved vitiligo indication, CMS has also conducted a Phase III trial in China of ruxolitinib phosphate cream for patients with mild to moderate atopic dermatitis, and the results were positive.
After 8 weeks of treatment, the proportion of subjects achieving an Investigator’s Global Assessment (IGA) score of 0 or 1 with at least a 2-point improvement from baseline was significantly higher with ruxolitinib cream than with placebo (63.0% vs 9.2%, P<0.001).
For the key secondary endpoint, the proportion of subjects achieving at least 75% improvement from baseline in Eczema Area and Severity Index (EASI 75) after 8 weeks was also significantly better with ruxolitinib cream than with placebo (78.0% vs 15.4%, P<0.001).
In terms of safety, most treatment-emergent adverse events (TEAEs) were mild or moderate, no TEAEs led to discontinuation of study drug, and the overall safety and tolerability profile was good.
CMS is now actively advancing the marketing application in China for ruxolitinib phosphate cream in atopic dermatitis. If approved, it will offer a new treatment option for the large patient population with atopic dermatitis in China.